Selected research
Industry Research
CAR-T Therapy For B-Cell Malignancies Industry Research Report 2026
Market perspective
The global CAR-T Therapy For B-Cell Malignancies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the CAR-T Therapy For B-Cell Malignancies market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the CAR-T Therapy For B-Cell Malignancies market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the CAR-T Therapy For B-Cell Malignancies market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of CAR-T Therapy For B-Cell Malignancies include IMCURE, JW Therapeutics, Johnson And Johnson, Novartis, Roche, CARsgen Therapeutics, Chongqing Precision Biotech, Gilead Sciences and HEBECELL, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global CAR-T Therapy For B-Cell Malignancies market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to CAR-T Therapy For B-Cell Malignancies.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
CAR-T Therapy For B-Cell Malignancies Market by Company
IMCURE
JW Therapeutics
Johnson And Johnson
Novartis
Roche
CARsgen Therapeutics
Chongqing Precision Biotech
Gilead Sciences
HEBECELL
Fosun Kite Bio
Legend Biotech
Beihai Biotechnology
AstraZeneca
Regeneron Pharmaceuticals
Kite Pharma
Celgene
Bristol Myers Squibb
Bluebird Bio
CAR-T Therapy For B-Cell Malignancies Segment by Type
Universal CAR-T
Dual Targets CAR-T
Gene Modified Enhanced CAR-T
Multi Targets CAR-T
Single Target CAR-T
CAR-T Therapy For B-Cell Malignancies Segment by Application
Multiple Myeloma
B-Cell Acute Lymphoblastic Leukemia
B-Cell Non-Hodgkin's Lymphoma
Others
CAR-T Therapy For B-Cell Malignancies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR-T Therapy For B-Cell Malignancies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CAR-T Therapy For B-Cell Malignancies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR-T Therapy For B-Cell Malignancies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of CAR-T Therapy For B-Cell Malignancies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Universal CAR-T
- Dual Targets CAR-T
- Gene Modified Enhanced CAR-T
- Multi Targets CAR-T
- Single Target CAR-T
Applications
- Multiple Myeloma
- B-Cell Acute Lymphoblastic Leukemia
- B-Cell Non-Hodgkin's Lymphoma
- Others
Companies covered
- IMCURE
- JW Therapeutics
- Johnson And Johnson
- Novartis
- Roche
- CARsgen Therapeutics
- Chongqing Precision Biotech
- Gilead Sciences
- HEBECELL
- Fosun Kite Bio
- Legend Biotech
- Beihai Biotechnology
- AstraZeneca
- Regeneron Pharmaceuticals
- Kite Pharma
- Celgene
- Bristol Myers Squibb
- Bluebird Bio
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 CAR-T Therapy For B-Cell Malignancies by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Universal CAR-T
- 2.2.3 Dual Targets CAR-T
- 2.2.4 Gene Modified Enhanced CAR-T
- 2.2.5 Multi Targets CAR-T
- 2.2.6 Single Target CAR-T
- 2.3 CAR-T Therapy For B-Cell Malignancies by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Multiple Myeloma
- 2.3.3 B-Cell Acute Lymphoblastic Leukemia
- 2.3.4 B-Cell Non-Hodgkin's Lymphoma
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 CAR-T Therapy For B-Cell Malignancies Breakdown Data by Type
- 3.1 Global CAR-T Therapy For B-Cell Malignancies Historic Market Size by Type (2021-2026)
- 3.2 Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Type (2027-2032)
4 CAR-T Therapy For B-Cell Malignancies Breakdown Data by Application
- 4.1 Global CAR-T Therapy For B-Cell Malignancies Historic Market Size by Application (2021-2026)
- 4.2 Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global CAR-T Therapy For B-Cell Malignancies Market Perspective (2021-2032)
- 5.2 Global CAR-T Therapy For B-Cell Malignancies Growth Trends by Region
- 5.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 CAR-T Therapy For B-Cell Malignancies Historic Market Size by Region (2021-2026)
- 5.2.3 CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Region (2027-2032)
- 5.3 CAR-T Therapy For B-Cell Malignancies Market Dynamics
- 5.3.1 CAR-T Therapy For B-Cell Malignancies Industry Trends
- 5.3.2 CAR-T Therapy For B-Cell Malignancies Market Drivers
- 5.3.3 CAR-T Therapy For B-Cell Malignancies Market Challenges
- 5.3.4 CAR-T Therapy For B-Cell Malignancies Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top CAR-T Therapy For B-Cell Malignancies Players by Revenue
- 6.1.1 Global Top CAR-T Therapy For B-Cell Malignancies Players by Revenue (2021-2026)
- 6.1.2 Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Players (2021-2026)
- 6.2 Global CAR-T Therapy For B-Cell Malignancies Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of CAR-T Therapy For B-Cell Malignancies Head Office and Area Served
- 6.4 Global CAR-T Therapy For B-Cell Malignancies Players, Product Type & Application
- 6.5 Global CAR-T Therapy For B-Cell Malignancies Manufacturers Established Date
- 6.6 Global CAR-T Therapy For B-Cell Malignancies Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
- 7.2 North America CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
- 7.4 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
- 8.2 Europe CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
- 8.4 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
- 9.2 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
- 9.4 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
- 10.2 South America CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
- 10.4 South America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
- 11.2 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
- 11.4 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 IMCURE
- 12.1.1 IMCURE Company Information
- 12.1.2 IMCURE Business Overview
- 12.1.3 IMCURE Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.1.4 IMCURE CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.1.5 IMCURE Recent Developments
- 12.2 JW Therapeutics
- 12.2.1 JW Therapeutics Company Information
- 12.2.2 JW Therapeutics Business Overview
- 12.2.3 JW Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.2.4 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.2.5 JW Therapeutics Recent Developments
- 12.3 Johnson And Johnson
- 12.3.1 Johnson And Johnson Company Information
- 12.3.2 Johnson And Johnson Business Overview
- 12.3.3 Johnson And Johnson Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.3.4 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.3.5 Johnson And Johnson Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.4.4 Novartis CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Roche
- 12.5.1 Roche Company Information
- 12.5.2 Roche Business Overview
- 12.5.3 Roche Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.5.4 Roche CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.5.5 Roche Recent Developments
- 12.6 CARsgen Therapeutics
- 12.6.1 CARsgen Therapeutics Company Information
- 12.6.2 CARsgen Therapeutics Business Overview
- 12.6.3 CARsgen Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.6.4 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.6.5 CARsgen Therapeutics Recent Developments
- 12.7 Chongqing Precision Biotech
- 12.7.1 Chongqing Precision Biotech Company Information
- 12.7.2 Chongqing Precision Biotech Business Overview
- 12.7.3 Chongqing Precision Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.7.4 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.7.5 Chongqing Precision Biotech Recent Developments
- 12.8 Gilead Sciences
- 12.8.1 Gilead Sciences Company Information
- 12.8.2 Gilead Sciences Business Overview
- 12.8.3 Gilead Sciences Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.8.4 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.8.5 Gilead Sciences Recent Developments
- 12.9 HEBECELL
- 12.9.1 HEBECELL Company Information
- 12.9.2 HEBECELL Business Overview
- 12.9.3 HEBECELL Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.9.4 HEBECELL CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.9.5 HEBECELL Recent Developments
- 12.10 Fosun Kite Bio
- 12.10.1 Fosun Kite Bio Company Information
- 12.10.2 Fosun Kite Bio Business Overview
- 12.10.3 Fosun Kite Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.10.4 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.10.5 Fosun Kite Bio Recent Developments
- 12.11 Legend Biotech
- 12.11.1 Legend Biotech Company Information
- 12.11.2 Legend Biotech Business Overview
- 12.11.3 Legend Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.11.4 Legend Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.11.5 Legend Biotech Recent Developments
- 12.12 Beihai Biotechnology
- 12.12.1 Beihai Biotechnology Company Information
- 12.12.2 Beihai Biotechnology Business Overview
- 12.12.3 Beihai Biotechnology Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.12.4 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.12.5 Beihai Biotechnology Recent Developments
- 12.13 AstraZeneca
- 12.13.1 AstraZeneca Company Information
- 12.13.2 AstraZeneca Business Overview
- 12.13.3 AstraZeneca Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.13.4 AstraZeneca CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.13.5 AstraZeneca Recent Developments
- 12.14 Regeneron Pharmaceuticals
- 12.14.1 Regeneron Pharmaceuticals Company Information
- 12.14.2 Regeneron Pharmaceuticals Business Overview
- 12.14.3 Regeneron Pharmaceuticals Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.14.4 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.14.5 Regeneron Pharmaceuticals Recent Developments
- 12.15 Kite Pharma
- 12.15.1 Kite Pharma Company Information
- 12.15.2 Kite Pharma Business Overview
- 12.15.3 Kite Pharma Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.15.4 Kite Pharma CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.15.5 Kite Pharma Recent Developments
- 12.16 Celgene
- 12.16.1 Celgene Company Information
- 12.16.2 Celgene Business Overview
- 12.16.3 Celgene Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.16.4 Celgene CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.16.5 Celgene Recent Developments
- 12.17 Bristol Myers Squibb
- 12.17.1 Bristol Myers Squibb Company Information
- 12.17.2 Bristol Myers Squibb Business Overview
- 12.17.3 Bristol Myers Squibb Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.17.4 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.17.5 Bristol Myers Squibb Recent Developments
- 12.18 Bluebird Bio
- 12.18.1 Bluebird Bio Company Information
- 12.18.2 Bluebird Bio Business Overview
- 12.18.3 Bluebird Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2021-2026)
- 12.18.4 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
- 12.18.5 Bluebird Bio Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst